GlassScriptPhysician profile
Michael C Finn
NPI 1811979974
$1,589.38
in general payments reported to CMS, 2019-2025
21 companies · $55.70 in 2025
The $55.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.79 · 2020: $33.15 · 2021: $769 · 2022: $185 · 2023: $297 · 2024: $192 · 2025: $55.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $661.53 | 2021 | |
| Medtronic, INC. | $230.87 | 2022-2025 | Cobalt Dr Mri Surescan, Attain Command + Surevalve, Micra |
| Janssen Pharmaceuticals, INC | $82.91 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $82.48 | 2022-2024 | Assure Wcd |
| Pfizer INC. | $80.60 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $60.96 | 2022-2024 | |
| Angiodynamics, INC. | $58.55 | 2022 | |
| Boston Scientific Corporation | $56.46 | 2021-2024 | |
| Abiomed | $40.00 | 2023 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $37.11 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.43 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.03 | 2025 | Lifevest |
| Itamar Medical INC | $20.12 | 2023 | Watchpatone |
| Kiniksa Pharmaceuticals International, Plc | $20.00 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $17.63 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $16.25 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $15.73 | 2025 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $14.67 | 2021 | |
| Elutia, INC. | $14.06 | 2020 | |
| Irhythm Technologies, INC. | $12.04 | 2022 | |
| Esperion Therapeutics, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Finn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.